Dottikon ES Holding Full Year 2025 Earnings: Beats Expectations

Dottikon ES Holding (VTX:DESN) Full Year 2025 Results

Key Financial Results

• Revenue: CHF394.5m (up 19% from FY 2024).
• Net income: CHF105.6m (up 31% from FY 2024).
• Profit margin: 27% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
• EPS: CHF7.64 (up from CHF5.84 in FY 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dottikon ES Holding Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 52%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Switzerland.

Performance of the Swiss Pharmaceuticals industry.

The company's shares are up 34% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Dottikon ES Holding that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.